Showing 181-190 of 9661 results for "".
- Meta-analysis: Topical Ivermectin, Encapsulated BPO Show Strongest Efficacy in Rosaceahttps://practicaldermatology.com/news/topical-ivermectin-encapsulated-benzoyl-peroxide-show-strongest-efficacy-in-rosacea-network-meta-analysis/2487668/A systematic review and network meta-analysis of randomized clinical trials suggests that topical ivermectin and encapsulated benzoyl peroxide (E-BPO) provide greater efficacy than metronidazole for adults with moderate to severe rosacea.
- FDA Grants SKYRIZI Approval to Children With Plaque Psoriasis and PsAhttps://practicaldermatology.com/news/fda-expands-skyrizi-approval-to-include-children-with-plaque-psoriasis-and-psoriatic-arthritis/2487657/The FDA has expanded the indication for SKYRIZI® (risankizumab-rzaa) to include children aged 6 years and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy, according to an announcement from AbbVie.
- FDA Expands ZORYVE Cream Approval to Children as Young as 2 Years With Plaque Psoriasishttps://practicaldermatology.com/news/fda-expands-zoryve-cream-approval-to-children-as-young-as-2-years-with-plaque-psoriasis/2487622/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics' supplemental New Drug Application (sNDA) expanding the indication for ZORYVE (roflumilast) cream 0.3% to include the topical treatment of plaque psoriasis, including intertriginous areas, in children as young as 2 yea
- Emblation Partners With DermLite to Expand Access to Dermoscopy for Podiatristshttps://practicaldermatology.com/news/emblation-partners-with-dermlite-to-expand-access-to-dermoscopy-for-podiatrists/2487590/Emblation has announced a new collaboration with DermLite that will make the DermLite DL1 dermatoscope available through the Swift store, expanding access to dermoscopy tools for podiatrists using the company's Swift microwave therapy platform.
- Skin Cancer Champions Earns Two Digital Health Awards for Patient Education and Community Engagementhttps://practicaldermatology.com/news/skin-cancer-champions-earns-two-digital-health-awards-for-patient-education-and-community-engagement/2487580/Skin Cancer Champions, an online community dedicated to supporting patients and caregivers affected by non-melanoma skin cancers, has received two Bronze Awards in the Spring 2026 Digital Health Awards, presented by the Health Information Resource Center (HIRC). The awards recognize the or
- Online Team-Based Care Matches In-Person Outcomes for Atopic Dermatitis: Analysishttps://practicaldermatology.com/news/online-team-based-care-matches-in-person-outcomes-for-atopic-dermatitis-analysis/2487582/A team-based connected health (TCH) model delivered online achieved equivalent improvements in atopic dermatitis (AD) severity compared with traditional in-person care, according to results from a randomized clinical trial. T
- Skin of Color Still Underrepresented Across Major Dermatology Image Searcheshttps://practicaldermatology.com/news/skin-of-color-still-underrepresented-across-major-dermatology-image-searches/2487573/Skin of Color (SOC) remains significantly underrepresented in image search results across major search engines, according to a recent Letter to the Editor published in the Journal of Drugs in Dermatology. Investigators building on earlier research in the area evaluated the first 5
- Global Integral Beauty Conference Marks Fifth Anniversary With Expanded International Programhttps://practicaldermatology.com/news/global-integral-beauty-conference-marks-fifth-anniversary-with-expanded-international-program/2487545/Global Integral Beauty (GIB) has announced that its 5th Global Integral Beauty Conference will be held on October 17, 2026, at the New York Marriott Marquis in New York, New York. Now entering its fifth year, the conference s
- AbbVie to Acquire Apogee Therapeutics in $10.9 Billion Immunology Dealhttps://practicaldermatology.com/news/abbvie-to-acquire-apogee-therapeutics-in-109-billion-immunology-deal/2487547/AbbVie announced a definitive agreement to acquire Apogee Therapeutics in an all-cash transaction valued at approximately $10.9 billion, a move the manufacturer said adds to its immunology pipeline and strengthens its presence in inflammatory diseases such as atopi
- Low Infection Risk Across Psoriasis Biologics Reported in Real-World Studyhttps://practicaldermatology.com/news/low-infection-risk-across-psoriasis-biologics-reported-in-real-world-study/2487541/A large real-world analysis published in the Journal of the American Academy of Dermatology indicates biologic therapies for psoriasis are associated with low overall infection risk, with ustekinumab and interleukin (IL)-23